Ian Schofield
Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs. As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ian Schofield
Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars
Companies wanting to compete in the newly off-patent adalimumab market in England have until Oct. 22 to submit their bids. They will need to offer “competitive prices” if they are to secure the highest share of sales to the national health service. At the same time, NHS trusts and clinical commissioning groups have been warned not to accept discounted interim offers from suppliers keen to get a foot in the door.
EU Policymakers Under Industry Pressure To 'Neuter' SPC Waiver Plan
“Vested interests” are pressuring EU policymakers to water down further European Commission plans for an exemption intended to allow generic and biosimilar firms to manufacture their versions of products for export while SPCs are still in effect, claims the industry sector body Medicines for Europe.
UK Appeal Panel Tells NICE To Revisit Scenesse Rejection
An appeals panel has upheld some of the objections to NICE’s decision not to recommend Clinuvel’s Scenesse for NHS funding in England. The HTA body’s Highly Specialized Technologies committee will now have to reconsider its guidance in light of the panel’s conclusions.
No-Deal Brexit Means ‘Re-Planning A Whole Industry,’ Says ABPI Chief
Mike Thompson, head of the Association of the British Pharmaceutical Industry, outlined his industry’s concerns over medicines stockpiling, batch testing, tariffs, regulatory collaboration and other issues at a parliamentary committee hearing on the implications of a no-deal Brexit.
CAR-T Funding: It's (Nearly) All About The Price In The UK
Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding
Scotland Launches New ‘Ultra-Orphan’ Assessment Pathway
The Scottish government is launching its new pathway for the assessment of “ultra-orphan” medicines by the HTA body, the Scottish Medicines Consortium, in an effort to speed up access to medicines for patients with very rare diseases
Advertisement